UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d)
of
The Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported) January
5, 2007
BODISEN
BIOTECH, INC.
|
(Exact
name of registrant as specified in its
charter)
|
Delaware
|
001-32616
|
98-0381367
|
(State
or other Jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
of
Incorporation)
|
|
Identification
No.)
|
North
Part of Xinquia Road, Yang Ling Agricultural High-Tech
|
Industries
Demonstration Zone, Yang Ling,
|
People's
Republic of China 712100
|
(Address
of Principal Executive Offices
|
|
86-29-87074957
|
(Registrant’s
Telephone Number, Including Area Code
|
|
Not
Applicable
|
(Former
Name or Former Address, if Changed Since Last
Report)
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other Events
Press
Release Clarifying Past Relationships with Consultancy Firms and
Affiliates
As
previously disclosed, on November 6, 2006, the Company received a letter
from
the American Stock Exchange (“Amex”) indicating that the Company is not in
compliance with certain continued listing standards. The letter specifically
conveyed the Amex’s view that the Company provided incomplete, misleading,
and/or inaccurate disclosure regarding its relationship with a consultancy
firm
and its affiliates. The identity of that consultancy firm is New York Global
Group.
Concurrent
with the filing of this Form 8-K, the Company is distributing a press release
clarifying its past relationship with New York Global Group and its affiliates.
The press release is attached to this report as Exhibit 99.2.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
Exhibit
No. Description
99.2 Press
Release dated January 5, 2007
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
|
|
|
BODISEN
BIOTECH,
INC. |
|
(Registrant) |
|
|
|
Date: January
5, 2007 |
|
/s/ Bo
Chen |
|
Bo
Chen |
|
Chairman,
Chief Executive Officer and President
|